Daily Newsletter

08 January 2024

Daily Newsletter

08 January 2024

Insilico teams up with Menarini for breast cancer KAT6 inhibitor

Menarini’s subsidiary Stemline will receive upfront and milestone payments, with a potential value exceeding $500m, along with royalties from sales.

Jenna Philpott January 05 2024

Insilico Medicine has joined forces with Menarini through its subsidiary Stemline Therapeutics to develop a small molecule KAT6A inhibitor to treat hormone-sensitive cancers, focusing on ER+/HER2- breast cancer. 

The collaboration involves an exclusive licensing agreement, providing Stemline with global rights to develop and commercialise a novel KAT6A inhibitor, which is designed using Insilico’s artificial intelligence (AI) platform.  

The molecule has shown positive results in preclinical studies, demonstrating a potent inhibition in multiple CDX and PDX models, as well as a good safety and efficacy profile. Insilico presented data on this development at the San Antonio Breast Cancer Symposium last month.  

Insilico will receive $12m in an upfront payment from Menarini, as well as milestone payments with a combined value of more than $500m and sales royalties. 

In September 2019, Insilico announced its AI-powered drug discovery system GENTRL, which was created in alliance with WuXi AppTec, a global open-access R&D and manufacturing platform, as well as professor Alán Aspuru-Guzik, who works in quantum computing and AI in chemistry. 

In the announcement accompanying the agreement, Menarini CEO Elcin Barker Ergun said: “Having brought the first innovation in endocrine therapy after almost 20 years to the US and Europe with elacestrant for ER+/HER2- breast cancer patients, our aim is to further augment patient outcomes, and targeting KAT6A can potentially serve that in breast cancer and beyond.” 

KAT6A proteins play a crucial role in regulating gene expression and are implicated in various cancers, including poor clinical outcomes of ER+/HER- breast cancers.  

Other companies are also looking at the same protein inhibition. Pfizer’s PF-07248144 is under development for the treatment of locally advanced or metastatic ER+/HER2- breast cancer, metastatic castration-resistant prostate cancer and metastatic non-small cell lung cancer (NSCLC).  

According to GlobalData’s Pharmaceutical Intelligence Center, PF-07248144 is currently being investigated in a Phase I clinical trial, with a Phase II trial planned. 

GlobalData is the parent company of Pharmaceutical Technology. 

State of the Biopharmaceutical Industry in 2024

Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close